Your browser doesn't support javascript.
loading
First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors.
Siu, Lillian L; Wang, Ding; Hilton, John; Geva, Ravit; Rasco, Drew; Perets, Ruth; Abraham, Anson K; Wilson, Douglas C; Markensohn, Julia F; Lunceford, Jared; Suttner, Leah; Siddiqi, Shabana; Altura, Rachel A; Maurice-Dror, Corinne.
Afiliación
  • Siu LL; Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada. Lillian.siu@uhn.ca.
  • Wang D; Department of Medical Oncology, Henry Ford Cancer Institute, Detroit, Michigan.
  • Hilton J; Department of Medicine, The Ottawa Hospital and University of Ottawa, Ottawa, Ontario, Canada.
  • Geva R; Department of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • Rasco D; Department of Clinical Research, START Center for Cancer Care, San Antonio, Texas.
  • Perets R; Division of Oncology, Clinical Research Institute at Rambam, Rambam Medical Center, Haifa, Israel.
  • Abraham AK; Department of Cancer and Cell Biology, Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
  • Wilson DC; Oncology Early Development, Merck & Co., Inc., Kenilworth, New Jersey.
  • Markensohn JF; Department of Profiling and Expression, Genetics and Pharmacogenomics, Merck & Co., Inc., South San Francisco, California.
  • Lunceford J; Oncology Early Development, Merck & Co., Inc., Kenilworth, New Jersey.
  • Suttner L; Oncology Early Development, Merck & Co., Inc., Kenilworth, New Jersey.
  • Siddiqi S; Oncology Early Development, Merck & Co., Inc., Kenilworth, New Jersey.
  • Altura RA; Oncology Early Development, Merck & Co., Inc., Kenilworth, New Jersey.
  • Maurice-Dror C; Oncology Early Development, Merck & Co., Inc., Kenilworth, New Jersey.
Clin Cancer Res ; 28(1): 57-70, 2022 01 01.
Article en En | MEDLINE | ID: mdl-34598945
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Receptor de Muerte Celular Programada 1 / Neoplasias Límite: Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Canadá
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Receptor de Muerte Celular Programada 1 / Neoplasias Límite: Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Canadá